Literature DB >> 10565918

Development of recombinant diagnostic reagents based on pp85(U14) and p86(U11) proteins to detect the human immune response to human herpesvirus 7 infection.

A Stefan1, M De Lillo, G Frascaroli, P Secchiero, F Neipel, G Campadelli-Fiume.   

Abstract

Human antibodies raised in response to human herpesvirus 7 (HHV-7) infection are directed predominantly to one or more HHV-7-infected cell proteins with apparent molecular masses of about 85 to 89 kDa. The genes that encode these proteins are unknown. However, several HHH-7 genes that possibly encode proteins in this molecular mass range have been identified. Thus, the proteins encoded by open reading frame U14 (85 kDa) and U11 (86 kDa) were expressed as recombinant proteins in bacteria. Of 13 human serum specimens that recognized the 85- to 89-kDa protein(s) of HHV-7-infected cells by immunoblotting, 12 were also reactive with recombinant pp85(U14) and 8 were reactive with p86(U11). It is concluded that (i) the HHV-7 immunodominant protein is pp85(U14) and (ii) the lack of posttranslational modifications in procaryotically expressed pp85 does not adversely affect the reactivity of human sera. Monoclonal antibody (MAb) 5E1 is an HHV-7-specific MAb directed to pp85(U14). Here, the HHV-7-specific epitope in pp85(U14) was finely mapped to the C' terminal region between amino acid residues 484 and 502. However, as indicated by the low level of reactivity of human sera with the HHV-7-specific epitope recognized by MAb 5E1, human sera recognize additional epitopes of pp85(U14) that are required for their full reactivity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10565918      PMCID: PMC85861     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  "Cytomegalovirus disease" in renal allograft recipients: is human herpesvirus 7 a co-factor for disease progression?

Authors:  H K Osman; J S Peiris; C E Taylor; P Warwicker; R F Jarrett; C R Madeley
Journal:  J Med Virol       Date:  1996-04       Impact factor: 2.327

2.  Seroconversion to human herpesvirus 6 and human herpesvirus 7 among Brazilian children with clinical diagnoses of measles or rubella.

Authors:  J B Black; E Durigon; K Kite-Powell; L de Souza; S P Curli; A M Afonso; M Theobaldo; P E Pellett
Journal:  Clin Infect Dis       Date:  1996-11       Impact factor: 9.079

3.  Evaluation of immunoassays for detection of antibodies to human herpesvirus 7.

Authors:  J B Black; T F Schwarz; J L Patton; K Kite-Powell; P E Pellett; S Wiersbitzky; R Bruns; C Müller; G Jäger; J A Stewart
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

Review 4.  The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution.

Authors:  U A Gompels; J Nicholas; G Lawrence; M Jones; B J Thomson; M E Martin; S Efstathiou; M Craxton; H A Macaulay
Journal:  Virology       Date:  1995-05-10       Impact factor: 3.616

5.  Cloning, restriction endonuclease mapping and partial sequence analysis of the genome of human herpesvirus 7 strain JI.

Authors:  V R Ruvolo; Z Berneman; P Secchiero; J Nicholas
Journal:  J Gen Virol       Date:  1996-08       Impact factor: 3.891

6.  Human herpesvirus 7 infection associated with central nervous system manifestations.

Authors:  S Torigoe; W Koide; M Yamada; E Miyashiro; K Tanaka-Taya; K Yamanishi
Journal:  J Pediatr       Date:  1996-08       Impact factor: 4.406

7.  Determination and analysis of the complete nucleotide sequence of human herpesvirus.

Authors:  J Nicholas
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  Polyvalent and monoclonal antibodies identify major immunogenic proteins specific for human herpesvirus 7-infected cells and have weak cross-reactivity with human herpesvirus 6.

Authors:  L Foà-Tomasi; E Avitabile; L Ke; G Campadelli-Fiume
Journal:  J Gen Virol       Date:  1994-10       Impact factor: 3.891

9.  Human herpesviruses 6 and 7 in salivary glands and shedding in saliva of healthy and human immunodeficiency virus positive individuals.

Authors:  D Di Luca; P Mirandola; T Ravaioli; R Dolcetti; A Frigatti; P Bovenzi; L Sighinolfi; P Monini; E Cassai
Journal:  J Med Virol       Date:  1995-04       Impact factor: 2.327

10.  Identification of an 85 kDa phosphoprotein as an immunodominant protein specific for human herpesvirus 7-infected cells.

Authors:  L Foà-Tomasi; M P Fiorilli; E Avitabile; G Campadelli-Fiume
Journal:  J Gen Virol       Date:  1996-03       Impact factor: 3.891

View more
  5 in total

1.  Herpes simplex virus glycoproteins H/L bind to cells independently of {alpha}V{beta}3 integrin and inhibit virus entry, and their constitutive expression restricts infection.

Authors:  Tatiana Gianni; Arianna Cerretani; Rebecca Dubois; Stefano Salvioli; Scott S Blystone; Felix Rey; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

2.  An immunoblot assay for detection of immunoglobulin M antibody to human herpesvirus 6.

Authors:  S LaCroix; J A Stewart; M E Thouless; J B Black
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

3.  Immune reactivity of human sera to the glycoprotein B of human herpesvirus 7.

Authors:  Michael Franti; Jean-Thierry Aubin; Guillemette De Saint-Maur; Haruhiko Kosuge; Koichi Yamanishi; Agnes Gautheret-Dejean; Antoine Garbarg-Chenon; Jean-Marie Huraux; Henri Agut
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

4.  Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain.

Authors:  Tatiana Gianni; Michele Amasio; Gabriella Campadelli-Fiume
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

5.  Development of an enzyme-linked immunosorbent assay for diagnosis of human herpesvirus-7 infection.

Authors:  Ana Lia Pradella Puglia; Murilo de Freitas Peigo; Fernando Russo Costa Bomfim; Ronaldo Luis Thomasini
Journal:  Rev Soc Bras Med Trop       Date:  2020-03-16       Impact factor: 1.581

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.